Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator dshade, r00kie, joboggi, Sir Francelote, zoomboom, Rosym
Search This Board:
Last Post: 10/31/2014 10:26:31 PM - Followers: 719 - Board type: Free - Posts Today: 0

   

Amarantus BioScience Holdings, Inc.

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia. The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard"). For further information, please visit www.Amarantus.comor connect with the company on FacebookTwitter, LinkedIn & Google+



            

 
PRESS RELEASES & NEWS ARTICLES

AMARANTUS BIOSCI INC(OTCMKTS:AMBS) is Making Moves 
OCTOBER 29, 2014 
Eltoprazine, LymPro and MANF: The Path Forward to Value Creation
 October 27, 2014    8:00 am
Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees
Oct 20, 2014 8:01 a.m.
AMARANTUS BIOSCI INC(OTCMKTS:AMBS) Developer of LymPro on Watch Here!
OCTOBER 16, 2014
Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
Also in Cramer's Portfolio: Amarantus Applies To FDA For MANF Orphan Drug Designation In Retinitis Pigmentosa 

Oct 16, 2014   9:30 a.m.
Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R)
Oct 9, 2014    6:01 a.m.
Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference
Oct 7, 2014    8:01 a.m.
Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024 : Opportunities for Leading Companies
Oct 1, 2014    9:16 p.m.
Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial
Sept 29, 2014     2:04 p.m.
Amarantus Shareholders Approve All Matters Voted Upon at Annual Shareholders Meeting
Sept 25, 2014     4:00 p.m.
Amarantus on road to commercializing AD test
September 23, 2014
Fundamental Milestones Ahead: Up-Listing from Strength
Thrursday, Sept. 18th 2014   12:30 p.m.
Amarantus Provides Program Update on Phase 2b Eltoprazine for Parkinson's Disease and Adult ADHD
Sept 17, 2014    8:00 a.m.
Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test(R)
Sept 12, 2014   10:30 a.m.
Amarantus to Present Orphan Ocular Data at Targeting Ocular Disorders Conference 2014
Sept 10, 2014   1:00 p.m.
Amarantus Announces Positive MANF Ocular Toxicology Data
Sept. 9, 2014   8:31 a.m.
Amarantus to Present at Sachs Associates 14th Annual Biotech in Europe Forum for Global Partnering and Investment

Sept 4, 2014   9:00 a.m.

Amarantus BioScience (Documentary Trailer)

Oct. 19, 2014
SNNLive - Amarantus  BioScience Holdings, Inc.
  Published on June 21, 2014

 

      Mr. Commissiong made a presentation on Sept. 12/14 at the Aegis Capital 2014                          Healthcare and Technology Conference at web cast live at 10:00 AM PT and
               available at http://wsw.com/webcast/aegis/ambs/ .
 
    
 
 
    
       

 

Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland

info@amarantus.com
pr@amarantus.com


Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc
.

408-737-2734 x101
ir@amarantus.com







 
VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols


Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179

           
info@vstocktransfer.com

www.VStockTransfer.com 


 
 
smiley  Amarantus anticipates launching LymPro in the fourth quarter of 2014. Amarantus plans to launch LymPro for RUO in the fourth quarter of 2014, primarily targeting pharmaceutical clinical trials. The company does not require Clinical Laboratory Improvement Amendments (CLIA) certification to launch LymPro in the RUO market.

smiley  "Amarantus is aiming to be first to market with an accurate, reliable and commercially- viable diagnostic blood test for Alzheimer's disease," said Gerald E. Commissiong. "Today's data gives us all the information we need to move full steam ahead with this strategy. We can now tailor our initial marketing efforts towards the $150M RUO market, primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials. We have nearly completed assembling the resources needed to launch LymPro to the RUO community in the fourth quarter. Thereafter, we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B"
 
 
smiley  The company will make a final decision on which version of LymPro (Version 1 or Version 2) to launch under the CLIA designation, which will be marketed to the general population, following an in-depth analysis from the full cohort of 140 subjects. The company anticipates launching LymPro under CLIA shortly after product launch in the RUO marketplace.

smiley  We will not be marketing for RUO. We will be conducting business development w/ pharma customers.
 
 
   Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from person to person. Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen” 
 
 
smiley   Gerald E. Commissiong  -  We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above – for the end of 2014 alone – will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.


 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
AMBS News: Statement of Changes in Beneficial Ownership (4) 10/29/2014 05:43:40 PM
AMBS News: Confidential Treatment Order (ct Order) 10/28/2014 03:48:02 PM
AMBS News: Statement of Changes in Beneficial Ownership (4) 10/14/2014 05:08:08 PM
AMBS News: Current Report Filing (8-k) 10/10/2014 04:15:12 PM
AMBS News: Current Report Filing (8-k) 10/06/2014 04:05:27 PM
PostSubject
#109587  Sticky Note JN - Why I'm Still Optimistic On LymPro Rosym 10/25/14 09:00:15 AM
#108674  Sticky Note Update from ASM Meeting: Sir Francelote 09/23/14 08:44:23 AM
#108320  Sticky Note New or Potential investors in AMBS r00kie 09/08/14 04:02:27 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#109628   Fla. scientists may have found Alzheimer's breakthrough $AMBS #LymPro http:/ zoomboom 10/31/14 10:26:31 PM
#109627   Well after two weeks of sideways trading that brharris 10/31/14 09:15:11 PM
#109626   The pps continues to rocket up there, towards joboggi 10/31/14 04:09:34 PM
#109625   Its not a matter of if....only a matter brharris 10/31/14 12:21:51 PM
#109624   C H E E R $ ! Aqua 10/31/14 10:19:08 AM
#109623   Can't wait for the uplist by strength. All Rosym 10/30/14 03:21:22 PM
#109622   Nice article, thanks for posting it. Many AMBS brharris 10/30/14 03:00:30 PM
#109621   What's the current share structure here? The_Phoenix 10/30/14 01:23:40 PM
#109620   AMARANTUS BIOSCI INC(OTCMKTS:AMBS) is Making Moves Rosym 10/30/14 10:33:14 AM
#109619   He accepted shares instead of cash. Only one brharris 10/30/14 12:03:56 AM
#109618   I see RLH bought 982,000 shares at .084, sumotrader 10/29/14 11:31:52 PM
#109617   Alzheimer's Association Alzheimer's Disease Facts and Figures Rosym 10/29/14 03:33:21 PM
#109616   About PsychoGenics (PGI) Rosym 10/29/14 08:06:02 AM
#109614   http://www.barchart.com/opinions/stocks/AMBS Aha, well, I will see you down a joboggi 10/28/14 10:35:43 PM
#109613   What did CEO DO NOW SELL THE FARM CHEAP breezy1 10/28/14 09:47:03 PM
#109612   per someone on another thread: JPetroInc 10/28/14 07:18:26 PM
#109610   JP. What exactly is this filing? What does Raddude_rude 10/28/14 05:28:07 PM
#109609   I believe it is possible but would require brharris 10/28/14 04:01:05 PM
#109608   UNITED STATES JPetroInc 10/28/14 03:53:18 PM
#109607   NEVER EVER. Up-listing without R/S is not realistic dsw 10/28/14 03:50:20 PM
#109606   Nasdaq up-listing without a R/S according to Gerald sante1 10/28/14 03:20:33 PM
#109605   Great list JP, thanks for sharing it. AMBS brharris 10/28/14 10:45:42 AM
#109604   ***** 15 Live Rounds in AMBS Chamber ***** JPetroInc 10/28/14 09:55:07 AM
#109603   If so, you should hurry up. With all sante1 10/28/14 12:08:45 AM
#109601   http://www.montridgellc.us New Institutional Investors Relation Firm. Thanks brharris 10/27/14 10:31:22 PM
#109599   This retest should be an excellent time to joboggi 10/27/14 09:50:57 PM
#109598   .0962 50 day MA joboggi 10/27/14 09:13:24 PM
#109597  Restored Interesting new connection with AMBS: http://www.montridgellc.com/about.html brharris 10/27/14 04:11:38 PM
#109596   Indeed, We are VERY VERY close mazennnn 10/27/14 11:24:39 AM
#109595   Many things occurring in the near term.... Stay brharris 10/27/14 09:15:40 AM
#109594   Eltoprazine, LymPro and MANF: The Path Forward to Crusade7 10/27/14 08:43:48 AM
#109592   great post BR JPetroInc 10/26/14 09:17:04 AM
#109591   aha, Manf was not on JN's mind in joboggi 10/25/14 09:41:12 PM
#109590   I could not agree more with you. The christjamin 10/25/14 02:24:13 PM
#109589   You must sit on the BOD or management Salexander1 10/25/14 12:30:58 PM
#109588   http://www.buckinstitute.org/focus-on-joana-neves-2014 brharris 10/25/14 11:18:37 AM
#109587   JN - Why I'm Still Optimistic On LymPro Rosym 10/25/14 09:00:15 AM
#109586   The article was published in Dec 2013, so AC2 10/25/14 09:00:09 AM
#109585   There is a really big hole in that joboggi 10/25/14 05:58:51 AM
#109584   I would have to say there is a Solantey 10/25/14 12:26:40 AM
#109583   $2,00 is the minimum for the Nasdaq. Is sante1 10/24/14 11:53:43 PM
#109582   "Orphan Drug Designations: Why You Should Care" by Solantey 10/24/14 08:30:45 PM
#109581   I see a hammer candle on the DAILY brharris 10/24/14 04:36:15 PM
#109580   zack.com said that the next earnings for AMBS Rosym 10/24/14 04:04:03 PM
#109579   Need 9.1 cent bid to sell for a hometownJOE 10/24/14 03:04:18 PM
#109578   Blast off myersvodka 10/24/14 01:50:10 PM
#109577   Did you ever find out anything more? dhafford 10/24/14 01:00:40 PM
#109576   Pull backs mean opportunity for me to add milobug 10/24/14 11:43:26 AM
#109575   Thanks buddy Sol*.. So sweet kind of you. christjamin 10/24/14 11:32:21 AM
#109574   You may get some push back on making brharris 10/24/14 10:40:41 AM
PostSubject